tradingkey.logo
tradingkey.logo
Search

ENDRA Life Sciences Inc

NDRA
Add to Watchlist
5.330USD
+0.330+6.60%
Close 06/30, 16:00ETQuotes delayed by 15 min
11.35MMarket Cap
LossP/E TTM

More Details of ENDRA Life Sciences Inc Company

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

ENDRA Life Sciences Inc Info

Ticker SymbolNDRA
Company nameENDRA Life Sciences Inc
IPO dateJun 28, 2017
CEOTokman (Alexander Y)
Number of employees21
Security typeOrdinary Share
Fiscal year-endJun 28
Address3600 Green Ct Ste 350
CityANN ARBOR
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code48105
Phone17343350468
Websitehttps://www.endrainc.com/
Ticker SymbolNDRA
IPO dateJun 28, 2017
CEOTokman (Alexander Y)

Company Executives of ENDRA Life Sciences Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.88K
-85.01%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.88K
-85.01%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--

FAQs

Who are the top five shareholders of ENDRA Life Sciences Inc?

The top five shareholders of ENDRA Life Sciences Inc are: Mr. Anthony DiGiandomenico

How many institutions hold shares of ENDRA Life Sciences Inc (NDRA)?

As of 2026Q1, 30 institutions hold shares of ENDRA Life Sciences Inc, with a combined market value of approximately 218.33K, accounting for 17.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 137855.00.